Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

CARDIOMYOPATHIES

First-in-class cardiac myosin inhibitor reduces symptoms of HCM

Nature Reviews Cardiology volume 17, page 677 (2020)Cite this article

Subjects

Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). These findings, from the EXPLORER-HCM trial, were presented at the ESC Congress 2020 and simultaneously published in The Lancet.

HCM is characterized by increased cardiac contractility, leading to ventricular hypertrophy and dynamic left ventricular outflow tract (LVOT) obstruction. Mavacamten is a first-in-class, small molecule, selective allosteric inhibitor of cardiac myosin ATPase developed to reduce actin–myosin cross-bridge formation. The drug specifically targets the pathological mechanism underlying HCM, with the aim of reducing contractility and improving myocardial energetics.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Olivotto, I. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759–769 (2020)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cardiology http://www.nature.com/nrcardio/

    Gregory B. Lim

Authors
  1. Gregory B. Lim
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Gregory B. Lim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim, G.B. First-in-class cardiac myosin inhibitor reduces symptoms of HCM. Nat Rev Cardiol 17, 677 (2020). https://doi.org/10.1038/s41569-020-00453-9

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41569-020-00453-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing